{"id":"NCT01713946","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","officialTitle":"A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-29","primaryCompletion":"2017-10-25","completion":"2017-10-25","firstPosted":"2012-10-25","resultsPosted":"2018-11-07","lastUpdate":"2018-11-07"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tuberous Sclerosis Complex-associated Refractory Seizures"],"interventions":[{"type":"DRUG","name":"RAD001","otherNames":["everolimus"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Antiepileptic drug (1 to 3 only)","otherNames":[]},{"type":"DRUG","name":"open label RAD001 (only used for post-extension phase)","otherNames":["open label everolimus"]}],"arms":[{"label":"Everolimus LT target of 3 - 7 ng/mL","type":"EXPERIMENTAL"},{"label":"Everolimus HT target of 9 -15 ng/mL","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.\n\nThe study consisted of 4 phases for each patient Baseline phase:\\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\\], Core phase \\[from randomization at Week 0 (V2) to Week 18 (V11)\\], Extension phase \\[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\\] and Post Extension phase \\[from end of Extension phase to end of study\\].","primaryOutcome":{"measure":"Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate","timeFrame":"Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)","effectByArm":[{"arm":"Everolimus LT Target of 3 to 7 ng/mL","deltaMin":28.2,"sd":null},{"arm":"Everolimus HT Target of 9 to 15 ng/mL","deltaMin":40,"sd":null},{"arm":"Placebo","deltaMin":15.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.008"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":104,"countries":["United States","Argentina","Australia","Belgium","Canada","Colombia","Denmark","France","Germany","Greece","Hungary","Ireland","Italy","Japan","Mexico","Netherlands","Norway","Poland","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["30169322","27613521","25682485"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":117},"commonTop":["Pyrexia","Stomatitis","Diarrhoea","Mouth ulceration","Upper respiratory tract infection"]}}